352 related articles for article (PubMed ID: 35267492)
1. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.
Fukui T; Tachihara M; Nagano T; Kobayashi K
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267492
[TBL] [Abstract][Full Text] [Related]
2. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.
Vavalà T; Mariniello A; Novello S
Transl Cancer Res; 2019 Jan; 8(Suppl 1):S48-S54. PubMed ID: 35117063
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
7. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
8. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
9. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
10. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
11. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
12. Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
Tanimura K; Yamada T; Horinaka M; Katayama Y; Fukui S; Morimoto K; Nakano T; Tokuda S; Morimoto Y; Iwasaku M; Kaneko Y; Uchino J; Yoneda K; Yano S; Sakai T; Takayama K
Cancer Lett; 2021 Dec; 522():119-128. PubMed ID: 34534615
[TBL] [Abstract][Full Text] [Related]
13. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
14. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
15. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
16. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
Makimoto G; Ohashi K; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):371-379. PubMed ID: 33106692
[TBL] [Abstract][Full Text] [Related]
18. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
19. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
20. RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report.
Yan H; Zeng L; Zhang Y
Heliyon; 2024 May; 10(9):e29928. PubMed ID: 38698976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]